| Literature DB >> 29307075 |
Karol Sikora1, Maciej Jaśkiewicz2, Damian Neubauer2, Marta Bauer2, Sylwia Bartoszewska2, Wioletta Barańska-Rybak3, Wojciech Kamysz2.
Abstract
In view of an appreciable increase in resistance of Staphylococcus aureus to the conventional antibiotics, it is desired to develop new effective drugs. Antimicrobial peptides (AMPs) seem to be attractive candidates. In general, AMPs samples used for in vitro studies consist of a peptide, counter-ion, and water. The presence of the counter-ion could be significant as it affects peptide secondary structure and biological activity. The purpose of this study was to estimate the impact of counter-ion on antistaphylococcal activity of selected AMPs (CAMEL, citropin 1.1, LL-37, pexiganan, temporin A). To do this, three kinds of salts were prepared, namely, acetates, hydrochlorides, and trifluoroacetates. In addition, the hemolytic activity against human red blood cells (hRBCs) and cytotoxicity (HaCaT) were determined. The results indicate that there is a substantial difference between different salts, but the pattern is not consistent for the peptides. In general, the antistaphylococcal activity decreased in the order: CAMEL > temporin A > pexiganan > citropin 1.1 ≫ LL-37. The highest selectivity indexes were determined for CAMEL hydrochloride, pexiganan acetate, and temporin A trifluoroacetate. This study shows how important is to take into account the kind of counter-ions when designing novel peptide-based antimicrobials.Entities:
Keywords: Antimicrobial peptides; Antistaphylococcal activity; CAMEL; Citropin 1.1; Counter-ion; LL-37; Pexiganan; Temporin A
Mesh:
Substances:
Year: 2018 PMID: 29307075 PMCID: PMC5917001 DOI: 10.1007/s00726-017-2536-9
Source DB: PubMed Journal: Amino Acids ISSN: 0939-4451 Impact factor: 3.520
Peptides used in this study
| Peptide | Sequence | Net charge | Average mass (Da) | MS analysis | ||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| CAMEL | KWKLFKKIGAVLKVL-NH2 | +6 | 1771.31 | 2 | 886.17 | 886.85 |
| 3 | 591.12 | 591.27 | ||||
| 4 | 444.59 | 444.89 | ||||
| Citropin 1.1 | GLFDVIKKVASVIGGL-NH2 | +2 | 1614.99 | 2 | 809.50 | 808.41 |
| 3 | 539.34 | 539.37 | ||||
| LL-37 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | +6 | 4493.33 | 4 | 1124.34 | 1124.31 |
| 5 | 899.67 | 899.68 | ||||
| 6 | 749.90 | 750.08 | ||||
| 7 | 642.91 | 643.19 | ||||
| 8 | 562.67 | 562.78 | ||||
| Pexiganan | GIGKFLKKAKKFGKAFVKILKK-NH2 | +10 | 2477.21 | 2 | 1239.61 | 1239.39 |
| 3 | 826.75 | 826.71 | ||||
| 4 | 620.31 | 620.34 | ||||
| 5 | 496.45 | 496.52 | ||||
| 6 | 413.88 | 414.11 | ||||
| Temporin A | FLPLIGRVLSGIL-NH2 | +2 | 1396.78 | 2 | 699.40 | 699.33 |
a Ion charge, b calculated mass-to-charge ratio, c measured mass-to-charge ratio
Counter-ions content in peptides (µg/mg and %mol)
| Peptide | Desired counter-ion | TFA− | AcO− | Cl− |
|---|---|---|---|---|
| CAMEL | TFA− | 272.32/100% | < LOD | < LOQ |
| AcO− | < LOQ | 146.62/98% | 3.22/2% | |
| Cl− | 6.67/2% | < LOD | 98.15/98% | |
| Citropin 1.1 | TFA− | 186.32/100% | < LOQ | < LOQ |
| AcO− | < LOQ | 57.76/100% | < LOQ | |
| Cl− | 6.42/3% | < LOD | 69.41/97% | |
| LL-37 | TFA− | 155.82/100% | < LOD | < LOD |
| AcO− | < LOQ | 157.52/100% | < LOQ | |
| Cl− | 2.30/2% | < LOQ | 177.56/98% | |
| Pexiganan | TFA− | 317.94/100% | < LOD | < LOQ |
| AcO− | < LOQ | 282.43/98% | 2.52/2% | |
| Cl− | 5.06/1% | < LOD | 114.09/99% | |
| Temporin A | TFA− | 162.54/100% | < LOD | < LOQ |
| AcO− | < LOQ | 63.8/94% | 2.47/6% | |
| Cl− | 4.73/3% | < LOD | 49.28/97% |
Molar extinction coefficients of the peptides
| Peptide | Molar extinction coefficient at 214 nm [cm−1 × M−1] |
|---|---|
| CAMEL | 47,653 |
| Citropin 1.1 | 19,623 |
| LL-37 | 55,919 |
| Pexiganan | 35,702 |
| Temporin A | 19,442 |
Peptide content and relative peptide content in peptides’ salts
| Peptide | Counter-ion | Mass fraction (mg/mg) | RSD (%) | Relative content |
|---|---|---|---|---|
| CAMEL | TFA− | 0.662 | 1.3 | 100% |
| AcO− | 0.705 | 3.1 | 106.5% | |
| Cl− | 0.624 | 1.2 | 94.2% | |
| Citropin 1.1 | TFA− | 0.703 | 3.0 | 100% |
| AcO− | 0.774 | 0.3 | 110.1% | |
| Cl− | 0.798 | 1.5 | 113.5% | |
| LL-37 | TFA− | 0.719 | 3.8 | 100% |
| AcO− | 0.791 | 2.7 | 110.1% | |
| Cl− | 0.857 | 1.4 | 119.2% | |
| Pexiganan | TFA− | 0.712 | 1.1 | 100% |
| AcO− | 0.816 | 1.9 | 114.6% | |
| Cl− | 0.793 | 2.6 | 111.3% | |
| Temporin A | TFA− | 0.853 | 0.5 | 100% |
| AcO− | 0.895 | 2.7 | 104.9% | |
| Cl− | 0.996 | 2.7 | 116.8% |
MIC values of the peptides [µg/mL]
| Peptide and counter-ion | CAMEL | Citropin 1.1 | LL-37 | Pexiganan | Temporin A | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TFA− | AcO− | Cl− | TFA− | AcO− | Cl− | TFA− | AcO− | Cl− | TFA− | AcO− | Cl− | TFA− | AcO− | Cl− | |
| Reference (5) | |||||||||||||||
| ATCC 25923 | 8 | 8 | 2 | 32 | 16 | 16 | > | > | > | 8 | 8 | 8 | 4 | 8 | 4 |
| ATCC 6538 | 2 | ≤ | ≤ | 16 | 4 | 4 | 128 | 64 | 64 | 4 | 2 | 4 | 4 | 4 | 4 |
| ATCC 6538/P | 4 | 1 | 1 | 16 | 8 | 8 | > | > | > | 8 | 4 | 8 | 8 | 4 | 8 |
| ATCC 9144 | 8 | 2 | 1 | 32 | 16 | 16 | > | > | > | 8 | 8 | 8 | 8 | 8 | 8 |
| ATCC 12598 | 4 | 2 | 1 | 16 | 8 | 8 | > | > | > | 16 | 8 | 8 | 4 | 4 | 4 |
| Clinical (24) | |||||||||||||||
| 001N (MRSA) | 4 | 2 | 2 | 16 | 16 | 16 | > | > | > | 16 | 8 | 8 | 8 | 4 | 8 |
| 001S (MRSA) | 4 | 4 | 2 | 16 | 16 | 16 | > | > | > | 8 | 8 | 8 | 4 | 4 | 4 |
| 002N | 4 | 4 | ≤ | 16 | 16 | 16 | > | > | > | 8 | 16 | 16 | 4 | 4 | 4 |
| 002S | 4 | 4 | 1 | 16 | 16 | 8 | > | > | > | 16 | 16 | 16 | 4 | 4 | 4 |
| 004N (MRSA) | 4 | 4 | 2 | 16 | 8 | 8 | > | > | > | 8 | 4 | 8 | 4 | 4 | 4 |
| 005S | ≤ | ≤ | ≤ | 2 | 2 | 2 | 2 | 2 | 4 | 1 | 1 | 1 | 4 | 4 | 4 |
| 013S | ≤ | ≤ | ≤ | 2 | 2 | 2 | 2 | 4 | 2 | 1 | 1 | 1 | 4 | 4 | 4 |
| 015N (MRSA) | 4 | 4 | 2 | 16 | 8 | 8 | > | > | > | 16 | 4 | 4 | 8 | 4 | 8 |
| 017N (MRSA) | 4 | 2 | 2 | 8 | 4 | 4 | > | > | > | 4 | 2 | 2 | 8 | 4 | 8 |
| 017S (MRSA) | 2 | 2 | 2 | 4 | 8 | 4 | > | > | > | 4 | 2 | 2 | 8 | 4 | 8 |
| 024N (MRSA) | ≤ | ≤ | ≤ | 2 | 2 | 2 | 2 | 4 | 2 | 1 | 1 | 1 | 4 | 4 | 4 |
| 030N | 4 | 4 | 4 | 16 | 16 | 16 | > | > | > | 16 | 16 | 8 | 4 | 4 | 4 |
| 033N | 4 | 4 | 4 | 16 | 8 | 16 | > | > | > | 16 | 8 | 16 | 4 | 2 | 4 |
| 039N | 4 | 4 | 4 | 16 | 8 | 16 | > | > | > | 8 | 16 | 8 | 4 | 2 | 4 |
| 043SC (MRSA) | 4 | 4 | 4 | 8 | 8 | 8 | > | > | > | 8 | 4 | 4 | 8 | 4 | 8 |
| 045N | 4 | 4 | 4 | 16 | 16 | 16 | > | > | > | 16 | 8 | 16 | 8 | 4 | 8 |
| 048S | 4 | 4 | 4 | 16 | 16 | 16 | > | > | > | 16 | 16 | 16 | 4 | 4 | 4 |
| 051N (MRSA) | 4 | 2 | 2 | 8 | 8 | 8 | > | > | > | 8 | 8 | 8 | 8 | 4 | 8 |
| 051S | 2 | 2 | 2 | 4 | 4 | 4 | > | > | > | 1 | 1 | 1 | 8 | 4 | 8 |
| 053N | 4 | 4 | 4 | 16 | 16 | 16 | > | > | > | 8 | 8 | 8 | 8 | 4 | 4 |
| 060S | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 4 | 2 | 4 |
| K19N | 4 | 2 | 1 | 16 | 16 | 16 | > | > | > | 8 | 16 | 16 | 8 | 8 | 8 |
| K46N | 4 | 4 | 4 | 16 | 16 | 16 | > | > | > | 8 | 8 | 8 | 8 | 4 | 8 |
| K50S | 1 | 1 | 1 | 2 | 1 | 1 | 4 | 2 | 4 | 1 | 2 | 1 | 8 | 4 | 4 |
| Mean value of MIC | ≤ 3.5 | ≤ 2.8 | ≤ 2.0 | 13.0 | 10.0 | 10.0 | > 411 | > 409 | > 409 | 8.4 | 7.1 | 7.4 | 5.9 | 4.2 | 5.7 |
≤ alone stands for MIC ≤ 0.25 µg/mL; > alone stands for MIC > 256 µg/mL
Fig. 1MIC distribution of peptides
Fig. 2Percentage of hemolysis of erythrocytes vs peptide concentration
IC50 values and selectivity indexes of the peptides
| Peptide | IC50 | Mean MIC values | Selectivity index (IC50/MIC) |
|---|---|---|---|
| CAMEL | |||
| TFA− | 3.32 | ≤ 3.5 | ≥ 0.95 |
| AcO− | 2.72 | ≤ 2.8 | ≥ 0.97 |
| Cl− | 2.49 | ≤ 2.0 | |
| Citropin 1.1 | |||
| TFA− | 3.02 | 13.0 | 0.23 |
| AcO− | 4.37 | 10.0 | 0.44 |
| Cl− | 4.12 | 10.0 | 0.41 |
| LL-37 | |||
| TFA− | 11.75 | > 411 | < 0.03 |
| AcO− | 22.65 | > 409 | < 0.06 |
| Cl− | 4.26 | > 409 | < 0.01 |
| Pexiganan | |||
| TFA− | 1.05 | 8.4 | 0.13 |
| AcO− | 10.60 | 7.1 |
|
| Cl− | 0.14 | 7.4 | 0.02 |
| Temporin A | |||
| TFA− | 7.91 | 5.9 |
|
| AcO− | 0.92 | 4.2 | 0.22 |
| Cl− | 3.43 | 5.7 | 0.60 |
Bold values are important in relation to the remaining results